Comparison of the long-term prognostic value of Cystatin C to other indicators of renal function, markers of inflammation and systolic dysfunction among patients with acute coronary syndrome

Kılıç, Teoman; Oner, Gökhan; Ural, Ertan; Yumuk, Zeki; Şahı̇n, Tayfun; Bildirici, Ulaş; Acar, Eser; Kozdağ, Güliz; Ural, Dilek

doi:10.1016/j.atherosclerosis.2009.05.015

Cited by 34 publications

(32 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, we propose that two potential mechanisms might be responsible for the association of cystatin C with no-reflow after PPCI. First, cystatin C has been implicated in the local and systemic inflammatory response, and high cystatin C levels have been found to be strongly associated with high concentrations of CRP [22][23][24]. In the present study, we also found a significant positive correlation between high cystatin C levels and increased hs-CRP concentrations.…”

Section: Serum Cystatin C Levels and Impaired Microvascular Perfusionsupporting

confidence: 75%

Association of serum cystatin C levels with myocardial perfusion and cardiac functional recovery in patients with anterior wall ST elevation myocardial infarction treated with primary coronary intervention

et al. 2015

View full text Add to dashboard Cite

This study sought to investigate the association of baseline serum cystatin C levels with myocardial perfusion and cardiac functional recovery in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). 108 patients with a first anterior STEMI who underwent PPCI were enrolled. Serum cystatin C was measured by immunoturbidimetric method. Patients were divided into two groups according to the median cystatin C levels on admission: group 1 (≥median, n = 54) and group 2 (

show abstract

Section: Serum Cystatin C Levels and Impaired Microvascular Perfusionsupporting

confidence: 75%

Association of serum cystatin C levels with myocardial perfusion and cardiac functional recovery in patients with anterior wall ST elevation myocardial infarction treated with primary coronary intervention

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Increased levels of CysC were found to be an independent predictor of CV events (cardiac death, nonfatal MI or unstable angina) at 6-month to 1-year follow-up of patients with non-ST elevation ACS compared to highsensitivity C-reactive protein (CRP), B-type natriuretic peptide (BNP), and sCr. 36,37 CysC was also found to be the most valuable parameter compared to CRP, N-terminal proBNP, and troponin I in prediction of LV dysfunction progression in patients with a first STEMI. 38 Moreover, in a group of 240 patients admitted to the hospital with acute exacerbation of HF, CysC level was significantly associated with risk of death or rehospitalization during 1-year followup.…”

Section: Cysc In Acs and Congestive Hfmentioning

confidence: 99%

Early Biomarkers of Renal Injury

Cruz

Goh

Haase-Fielitz

et al. 2010

Congestive Heart Failure

View full text Add to dashboard Cite

Congest Heart Fail. 2010;16(4)(suppl 1):S25–S31. ©2010 Wiley Periodicals, Inc.Cardiorenal syndrome (CRS) refers to pathophysiologic interaction of the heart and kidney and is associated with acute kidney injury (AKI) and high mortality. Cardiac surgery or acute decompensated heart failure and radiocontrast‐induced nephropathy are common clinical scenarios of CRS. Unfortunately, established functional biomarkers of glomerular filtration rate such as serum creatinine, urea, and diuresis delay AKI diagnosis by 24 to 48 hours. Novel renal biomarkers indicating tubular injury are emerging and may have wide implications. This review focuses on several novel renal biomarkers with the most promising biologic characteristics and clinical evidence for their AKI predictive ability: neutrophil gelatinase‐associated lipocalin, kidney injury molecule‐1, interleukin 18, and fatty acid–binding proteins. The value of each biomarker is reviewed on currently available clinical data in typical settings of CRS. These markers might extend the therapeutic window during which timely and individualized patient management might be possible.

show abstract

“…Several studies currently evaluate the prognostic performances of cardiovascular biomarkers measured in the acute phase of a myocardial infarction (MI) on case series including both patients with ST-elevation myocardial infarction (STEMI) and MI with non-ST-elevation at electrocardiogram (ECG) (NSTEMI) [1,2]. However the mixing of these two populations of patients contrasts with the definition of acute MI stating STEMI and NSTEMI as two distinct pathophysiologic entities according to the presence/absence of electrocardiographic ischemic changes [3].…”

Section: Introductionmentioning

confidence: 99%

New insights in the pathophysiology of acute myocardial infarction detectable by a contemporary troponin assay

Ferraro

Biganzoli

Marano

et al. 2013

Clinical Biochemistry

View full text Add to dashboard Cite

Objectives: ST-elevation and non-ST-elevation myocardial infarction (STEMI, NSTEMI) are considered two distinct pathophysiologic entities. We evaluated cardiac troponin I (cTnI) release in STEMI and NSTEMI using a "contemporary" (CV > 10 to 20% at the 99th percentile concentration) cTnI assay for patients undergoing early percutaneous coronary intervention (PCI).Design and methods: 856 patients with suspected acute coronary syndrome consecutively admitted to the Emergency Department of the Maggiore Hospital of Novara (225 STEMI and 135 NSTEMI) were selected according to: 1) early (≤4 h from admission) and successful PCI; and 2) cTnI measurements at ED presentation and within 24 h. The influence of the MI type on cTnI concentrations at baseline and after PCI as well as the velocity of cTnI [cTnI V = absolute increase (after log conversion of cTnI measurements) / delay between the two measurements] was studied by multiple regression analysis, adjusting for patient parameters.Results: A statistically significant interaction between MI type and time from symptoms was reported on cTnI concentrations (p b 0.0001): STEMI and NSTEMI differed for cTnI releases at admission and after revascularization. Higher cTnI V in STEMI was detectable in patients admitted within 6 h from symptoms. Baseline cTnI concentrations were lower in patients with a history of coronary artery disease (CAD) and increased with aging (p b 0.0001). In the elderly (>75 years), the cTnI V was significantly increased.Conclusion: STEMI and NSTEMI patients have different patterns and dynamics of cTnI release influenced by the interaction with time from symptoms, by aging and history of CAD.

show abstract

Comparison of the long-term prognostic value of Cystatin C to other indicators of renal function, markers of inflammation and systolic dysfunction among patients with acute coronary syndrome

Cited by 34 publications

References 40 publications

Association of serum cystatin C levels with myocardial perfusion and cardiac functional recovery in patients with anterior wall ST elevation myocardial infarction treated with primary coronary intervention

Association of serum cystatin C levels with myocardial perfusion and cardiac functional recovery in patients with anterior wall ST elevation myocardial infarction treated with primary coronary intervention

Early Biomarkers of Renal Injury

New insights in the pathophysiology of acute myocardial infarction detectable by a contemporary troponin assay

Contact Info

Product

Resources

About